Oridonin (Ori), a covalent NLRP3 inflammasome inhibitor [167], has been shown to ameliorate noise-induced HL and kanamycin + furosemide-induced HL [155, 160, 168]. Here, NLRP3 is linked to Hodgkins lymphoma.